ACADIA raised its full-year DAYBUE sales outlook while maintaining its NUPLAZID guidance. Garner said ACADIA expects less than 50% of its stated $700 million DAYBUE sales target for 2028 to come from Europe. ACADIA estimates remlifanserin could have $4 billion in peak sales potential across Alzheimer’s disease psychosis and Lewy body dementia psychosis. About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia.